<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03055169</url>
  </required_header>
  <id_info>
    <org_study_id>2009_58</org_study_id>
    <secondary_id>2010-A00997-32</secondary_id>
    <nct_id>NCT03055169</nct_id>
  </id_info>
  <brief_title>TCF7L2 Polymorphisms Influence on Glycemic Control in ICU Patients With Organ Failure</brief_title>
  <acronym>READIAB-G4</acronym>
  <official_title>TCF7L2 Polymorphisms Influence on Glycemic Control in ICU Patients With Organ Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Lille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Lille</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the link between genetic polymorphisms as r7903146, rs12255372 of TCF7L2
      gene and the risk of developing hyperglycemia during Intensive care unit stay
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 2012</start_date>
  <completion_date type="Actual">August 2017</completion_date>
  <primary_completion_date type="Actual">August 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>value of the odds ratio associated with the relationship between a polymorphism TCF7L2 gene and the occurrence of hyperglycemia</measure>
    <time_frame>one year after inclusion</time_frame>
    <description>find a link between genetic polymorphism of TCF7L2 and the risk of developing hyperglycemia in intensive care patients with a least one organ dysfunction.
the hyperglycemia is defined fasting glucose&gt; 1.26 g / l twice or need for treatment with insulin)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in inflammatory markers</measure>
    <time_frame>one year after inclusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in serum lipid profile</measure>
    <time_frame>one year after inclusion</time_frame>
    <description>Changes in cholesterol total, LDL cholesterol, HDL cholesterol and triglycerides</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in liver enzymes</measure>
    <time_frame>one year after inclusion</time_frame>
    <description>Changes in total alanine transaminase (ALT) total gamma-GT total aspartate transaminase (AST)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin Resistance (HOMA)</measure>
    <time_frame>one year after inclusion</time_frame>
    <description>Calculated using the updated homeostasis model assessment (HOMA) calculator.Higher numbers indicate higher insulin resistance. There are no established cutoffs indicating impaired resistance.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Blood samples collection</measure>
    <time_frame>5 years</time_frame>
    <description>the blood samples collection will created for next research Both on diabetes and / or insulin resistance as its determinisms, at the ICU patient</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of patients with genotype TCF7L2 by PCR</measure>
    <time_frame>5 years</time_frame>
    <description>the prevalence of TCF7L2, in the intensive care patient or not glycemic control, and compared to the values found in the general population.
the TCF7L2 genes will be evaluated by the Taqman method (7900HT Fast Real-Time PCR System-Applied BioSystem).</description>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">994</enrollment>
  <condition>Genetic Predisposition to Disease</condition>
  <condition>Hyperglycemia</condition>
  <condition>Intensive Care Unit Syndrome</condition>
  <condition>Multiple Organ Failure</condition>
  <arm_group>
    <arm_group_label>intensive care patients</arm_group_label>
    <description>patients with a least one organ dysfunction</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>genetic analysis</intervention_name>
    <arm_group_label>intensive care patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>blood and stools samples</intervention_name>
    <arm_group_label>intensive care patients</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      blood, plasma, mononuclear cells, DNA
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        patients admitted in ICU &gt; 48h with at least one organ dysfunction
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  admission in ICU&gt;48h

          -  at least one organ dysfunction

        Exclusion Criteria:

          -  age&lt; 18 years

          -  pregnant women

          -  admission less than 48h
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mercedes Jourdain, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Lille</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU Cote de Nâcre</name>
      <address>
        <city>Caen</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Roger Salengro, CHRU de Lille</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH Victor Provot</name>
      <address>
        <city>Roubaix</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Charles Nicolle</name>
      <address>
        <city>Rouen</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH Tourcoing</name>
      <address>
        <city>Tourcoing</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 13, 2016</study_first_submitted>
  <study_first_submitted_qc>February 13, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">February 16, 2017</study_first_posted>
  <last_update_submitted>May 2, 2018</last_update_submitted>
  <last_update_submitted_qc>May 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>hyperglycemia</keyword>
  <keyword>Multiple Organ Failure</keyword>
  <keyword>biobank</keyword>
  <keyword>diabetes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperglycemia</mesh_term>
    <mesh_term>Disease Susceptibility</mesh_term>
    <mesh_term>Genetic Predisposition to Disease</mesh_term>
    <mesh_term>Multiple Organ Failure</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

